Radiation plus targeted drugs for breast cancer that spread to the brain
Original title: Efficacy and safety of brain radiotherapy combined with antibody-drug conjugates in patients with HER2-positive breast cancer brain metastases.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Doctors looked back at care people already got, not a planned trial.
The short version
In 35 people, brain tumors often shrank or stopped growing with this care.
What was studied. Doctors in China looked back at the records of 35 people. All had HER2 positive breast cancer that spread to the brain, and all got brain radiation plus one of two drugs, T-DXd or T-DM1.
What they found. Brain tumors got smaller in 74.3% of the people. Tumors shrank or stayed the same in 94.3%. People who got T-DXd went longer before their cancer grew than people who got T-DM1. Common side effects were low appetite in 23% and tiredness in 11%.
What this means, and what it doesn't
What it could mean: Radiation plus one of these drugs may help control tumors in the brain. Both drugs are already used in everyday care for this cancer. Your doctor can tell you if either one fits your case.
What it doesn't mean: This is not a cure, and it is not proof that one drug is better. Doctors only looked back at records from one hospital. They did not run a planned trial, and people were not picked at random. So the two groups may have differed in ways that changed the results. The authors say larger studies at many hospitals are still needed.
Source: PubMed, August 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.